Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
15 pending office actions • 13 clients • 15 examiners • 13 art units • 0 of 15 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Synergy IP Group AG reports 131 career applications in Biotechnology & Pharmaceuticals and 13 pending office actions. The profile combines a defined application history with an active current docket in the same technology area.
The resolved allowance rate is 59.7%, and the average is 3.8 office actions per allowance. The allowance figure describes the reported resolution outcome, while the office-action average indicates that allowances have generally followed several prosecution events. These metrics should be considered together because they address different aspects of prosecution performance.
The record can help practitioners frame diligence questions about portfolio outcomes and workload. It does not identify the reasons for allowance or non-allowance, the nature of the claims, or the complexity of individual matters, so the figures do not by themselves predict a new application’s path.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (13%) |
| §103 only | 6 (40%) |
| Double-patenting + other | 2 (13%) |
| Multi-statute (no §101) | 5 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +56.1% |
| SHI, GENBIN | 1 | — | — |
| CRAIGO, BAHAR ALAWI | 1 | 47.3% | +27.2% |
| JACKSON III, WALTER | 1 | 50.0% | +0.0% |
| HOLTZCLAW, MICHAEL T. | 1 | 78.0% | +15.5% |
| MOORE, MARGARET G | 1 | 68.1% | +15.6% |
| FAN, LYNN Y | 1 | 47.3% | +49.8% |
| PETERS, ALEC JON | 1 | 67.4% | +54.8% |
| WELLES, COLMAN THOMAS | 1 | 26.9% | +65.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17595393 | METHOD FOR PRODUCING NANOPARTICLES | HOLT, ANDRIAE M | 5d |
| 18725818 | Ovomucoid for use in a method of managing blood coagulation | ESPINOSA, CLAUDIA EDILMA | — |
| 18716156 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | SHI, GENBIN | — |
| 18710538 | COMPOSITION FOR PREVENTION OR TREATMENT OF MULTIPLE MYELOMA COMPRISING NOVEL TETRACYCLIC TRITERPENE COMPOUND AS ACTIVE INGREDIENT | CRAIGO, BAHAR ALAWI | — |
| 18423327 | 3D ARTIFICIAL SKIN MODEL AND METHOD FOR PRODUCING THE SAME | JACKSON III, WALTER | — |
| 18566112 | METHOD AND APPARATUS FOR SELECTIVE APPLICATION OF STIMULUS LIGHT | HOLTZCLAW, MICHAEL T. | — |
| 18549476 | TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE | FAN, LYNN Y | — |
| 18317940 | PHARMACEUTICAL COMPOSITIONS IN LYOPHILIZED FORM | WELLES, COLMAN THOMAS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18777616 | TOPICAL COMPOSITION FOR ADMINISTRATION TO NAILS | GEMBEH, SHIRLEY V | — |
| 18725818 | Ovomucoid for use in a method of managing blood coagulation | ESPINOSA, CLAUDIA EDILMA | — |
| 18710538 | COMPOSITION FOR PREVENTION OR TREATMENT OF MULTIPLE MYELOMA COMPRISING NOVEL TETRACYCLIC TRITERPENE COMPOUND AS ACTIVE INGREDIENT | CRAIGO, BAHAR ALAWI | — |
| 18566112 | METHOD AND APPARATUS FOR SELECTIVE APPLICATION OF STIMULUS LIGHT | HOLTZCLAW, MICHAEL T. | — |
| 18557303 | COMPOSITIONS AND METHODS OF REDUCING AGGREGATION OF MOLECULES | MOORE, MARGARET G | — |
| 18549476 | TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE | FAN, LYNN Y | — |
| 18000516 | PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND APPLICATION THEREOF | PETERS, ALEC JON | — |
| 18317940 | PHARMACEUTICAL COMPOSITIONS IN LYOPHILIZED FORM | WELLES, COLMAN THOMAS | — |
| Art Unit | Apps |
|---|---|
| 1612 | 3 |
| 1615 | 1 |
| 1654 | 1 |
| 1628 | 1 |
| 1699 | 1 |
| 1638 | 1 |
| 3796 | 1 |
| 1765 | 1 |
| 1759 | 1 |
| 1641 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18777616 | TOPICAL COMPOSITION FOR ADMINISTRATION TO NAILS | Mim Pharma GmbH | GEMBEH, SHIRLEY V | 1615 | §103 | Final Rejection | — | Pending | Jul 19, 2024 |
| 18725818 | Ovomucoid for use in a method of managing blood coagulation | Solution Shop AG | ESPINOSA, CLAUDIA EDILMA | 1654 | §101§102§112Other | Non-Final OA | — | Pending | Jul 01, 2024 |
| 18716156 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | Nanjing Zenshine Pharmaceuticals Co., Ltd. | SHI, GENBIN | 1628 | §103§112 | Non-Final OA | — | Pending | Jun 04, 2024 |
| 18710538 | COMPOSITION FOR PREVENTION OR TREATMENT OF MULTIPLE MYELOMA COMPRISING NOVEL TETRACYCLIC TRITERPENE COMPOUND AS ACTIVE INGREDIENT | Industry Foundation Of Chonnam National University | CRAIGO, BAHAR ALAWI | 1699 | §102§103 | Non-Final OA | — | Pending | May 15, 2024 |
| 18423327 | 3D ARTIFICIAL SKIN MODEL AND METHOD FOR PRODUCING THE SAME | Korea Advanced Institute Of Science And Technology | JACKSON III, WALTER | 1638 | §102§103 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18566112 | METHOD AND APPARATUS FOR SELECTIVE APPLICATION OF STIMULUS LIGHT | Dopavision GmbH | HOLTZCLAW, MICHAEL T. | 3796 | §102§103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18557303 | COMPOSITIONS AND METHODS OF REDUCING AGGREGATION OF MOLECULES | Ludwig-Maximilians-Universitaet Muenchen | MOORE, MARGARET G | 1765 | §103 | Final Rejection | — | Pending | Oct 26, 2023 |
| 18549476 | TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE | UNIVERSITEIT GENT | FAN, LYNN Y | 1759 | §101§102§103 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18000516 | PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND APPLICATION THEREOF | Shanghai Bao Pharmaceuticals Co., Ltd. | PETERS, ALEC JON | 1641 | §103 | Non-Final OA | — | Pending | May 26, 2023 |
| 18317940 | PHARMACEUTICAL COMPOSITIONS IN LYOPHILIZED FORM | Breath Therapeutics GmbH | WELLES, COLMAN THOMAS | 1612 | §103 | Non-Final OA | — | Pending | May 16, 2023 |
| 18042460 | JET IMPINGEMENT REACTOR | Leon-Nanodrugs GmbH | SORKIN, DAVID L | 1774 | §103 | Non-Final OA | — | Pending | Feb 22, 2023 |
| 17999851 | METHOD FOR PRODUCING A LIPOSOME DISPERSION | Leon-Nanodrugs GmbH | ATKINSON, JOSHUA ALEXANDER | 1612 | §103DP | Final Rejection | 28d | Pending | Nov 24, 2022 |
| 17778007 | PROCESS FOR THE PREPARATION OF DISPERSIONS COMPRISING INHALABLE IMMUNOSUPPRESSIVE ACTIVE INGREDIENTS | ZAMBON S.P.A. | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §103DP | Non-Final OA | — | Pending | May 19, 2022 |
| 17776226 | ADAPTER FOR A DRUG MIXING AND INJECTION SYSTEM | Activoris Medizintechnik GmbH | PAZ ESTEVEZ, GUILLERMO G | 3783 | §103 | Final Rejection | — | Pending | May 12, 2022 |
| 17595393 | METHOD FOR PRODUCING NANOPARTICLES | Leon-Nanodrugs GmbH | HOLT, ANDRIAE M | 1614 | §103§112 | Final Rejection | 5d | Pending | Nov 16, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial59.7% of resolved applications prosecuted by Synergy Ip Group AG were allowed, across 131 applications in USPTO records.
3.80 office actions per allowed application on average.
15 pending office actions as of October 2026, for 13 clients, before 15 examiners in 13 art units.
